Salivary HLA-DQA1*05 Genotyping and Anti-TNF Treatment Outcomes in Inflammatory Bowel Disease: An Ambispective Cohort Study with Long-Term Follow-Up
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Objectives: HLA-DQA1*05 carriage has been associated with immunogenicity to anti-TNF agents in inflammatory bowel disease (IBD), but real-world data are inconsistent. We assessed whether carriage, determined by salivary genotyping, was associated with anti-TNF effectiveness, persistence and safety. Ambispective here denotes prospective ascertainment of the exposure combined with retrospective capture of outcomes. Methods: This was a single-centre ambispective cohort study of 170 adults with IBD treated with infliximab or adalimumab as their first biologic. HLA-DQA1*05 was genotyped prospectively from saliva (July 2024–April 2025); outcomes were retrieved retrospectively. Primary non-response (PNR), secondary loss of response (SLOR), treatment persistence and adverse events were compared by genotype using Kaplan–Meier and multivariable Cox analyses. Results: Of 167 patients with a conclusive genotype, 74 (44.3%) were carriers; median treatment exposure was 78.5 months. PNR occurred in 12.2% of carriers and 7.5% of non-carriers (odds ratio [OR] 1.70, 95% confidence interval [CI] 0.60–4.81), and SLOR in 53.8% and 47.7% of initial responders (OR 1.28, 95% CI 0.67–2.44). Carriage was not associated with time to SLOR (adjusted hazard ratio [HR] 1.76, 95% CI 0.97–3.21) or with all-cause discontinuation (adjusted HR 0.98, 95% CI 0.62–1.55). Conclusions: In this selected, real-world cohort with long-term follow-up, HLA-DQA1*05 carriage determined in saliva was not associated with anti-TNF failure or treatment persistence, although clinically relevant effects are not excluded. Establishing the clinical utility of HLA-DQA1*05 testing will require prospective genotyping before treatment, with systematic immunogenicity assessment.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm15229064
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7236748425
